Metastatic Clear Cell Renal Cell Carcinoma (RCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Metastatic Clear Cell Renal Cell Carcinoma (RCC) Market Outlook

Thelansis’s “Metastatic Clear Cell Renal Cell Carcinoma (RCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Clear Cell Renal Cell Carcinoma (RCC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Metastatic Clear Cell Renal Cell Carcinoma (RCC) Overview

Renal cell carcinoma (RCC), the eighth most common malignancy affecting adults, accounts for between 3% and 4% of new cancer cases in the United States. The classic clinical presentation of flank pain, hematuria, and a palpable flank mass are comparatively uncommon (5–10% of cases). However, clinical symptomatology may be relatively nonspecific. For example, anorexia, tiredness, weight loss, or fever of unknown origin · The clear cell histologic subtype remains the most common representing approximately 70% of all renal tumors and an even more significant proportion of patients with metastatic RCC (>80%). The vast majority of clear cell RCC is characterized by biallelic loss of function of the von Hippel Lindau (VHL) tumor suppressor gene. Prognosis is generally reflected in staging severity, with the lower-stage disease associated with longer survival rates. The prediction is noticeably adversely affected by the spread of the tumor beyond the renal fascia and into the retroperitoneum (TNM T3a and higher) · The more common sites of metastases as reported in stage IV disease (TNM T4 or N1+ M1 disease) are the lung (69%), bone (43%), liver (34%), lymph nodes (22%), adrenal gland (19%), brain (7%), and thyroid, skin, and bladder (< 1% each)

• The prevalence of patients present with localized disease. However, approximately one-third present with locally advanced or metastatic disease, and up to 30% of patients undergoing surgical resection will experience recurrent disease.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: